Veeva Systems has acquired Copli and launched a new AI-powered content review platform designed to streamline medical, legal and regulatory review processes.

Veeva Systems has acquired Danish life sciences software company Copli and launched Veeva Falcon MLR, an artificial intelligence-powered platform designed to automate parts of the medical, legal and regulatory review process for pharmaceutical content.

The acquisition expands Veeva’s growing portfolio of AI-enabled tools and brings Copli’s agentic review technology into the Veeva ecosystem. Financial terms of the deal were not disclosed.

Medical, legal and regulatory review remains one of the most time-intensive processes in pharmaceutical marketing and medical communications, with companies required to ensure promotional and medical materials comply with approved product labels and local regulatory requirements before publication.

According to Veeva, Falcon MLR is designed to automate routine review activities by conducting compliance checks against approved labelling and regulatory standards. The company said the technology could significantly reduce manual review work and accelerate approval timelines for content destined for healthcare professionals and patients.

Jacob Scheel-Bech, chief executive officer at Copli, said: “Our breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval.”

He added: “As part of Veeva, we can scale our vision for MLR transformation. Veeva Falcon MLR brings compliance at speed to the industry with intelligent agents that work seamlessly with Veeva PromoMats.”

The new platform integrates with Veeva PromoMats, the company’s content management and approval system used across the life sciences industry.

Emma Hyland, vice president, Veeva Commercial Content, said: “The MLR process has long been a significant bottleneck in getting critical information to patients and doctors.”

She added: “With Veeva Falcon MLR, our customers can speed up the entire review cycle, automating routine labor so reviewers can become strategic advisors.”

Veeva said the platform is intended for use by pharmaceutical marketing teams, MLR reviewers and external agencies involved in content creation and approval workflows.

The launch reflects wider industry efforts to apply artificial intelligence to highly regulated processes across drug development and commercial operations. Companies are increasingly exploring AI tools to reduce administrative workloads, improve efficiency and accelerate access to information, although adoption remains dependent on maintaining compliance with regulatory standards.

Veeva said Falcon MLR is available immediately following the acquisition. The company claims the technology has the potential to eliminate more than 70% of manual MLR review labour over the next five years, although real-world adoption and performance data have not yet been disclosed.